Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dato-DXd Provides Numerical, But Not Significant, OS Benefit in Pretreated Advanced NSCLC

May 28th 2024

Dato-DXd elicited a clinically meaningful but not statistically significant improvement in overall survival in pretreated, advanced non–small cell lung cancer.

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.

Challenges and Unmet Needs in HER2-Mutated NSCLC

May 22nd 2024

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

Adverse Events Associated With TKIs in HER2-Mutated NSCLC

May 22nd 2024

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Guardant360 CDx Gains European Union Certification for Tumor Profiling in Solid Tumors

May 22nd 2024

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Concurrent NSCLC Biomarker Testing at Diagnosis

May 21st 2024

Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.

Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing

May 21st 2024

Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the crucial role of molecular testing in disease diagnosis, focusing on the significance of rapid turnaround times and the ability of liquid biopsies to address time-sensitive diagnostic needs.

Dr Liu Previews ASCO 2024 Lung Cancer Data

May 17th 2024

Stephen V. Liu, MD, discusses studies being presented at the 2024 ASCO Annual Meeting that may provide valuable insights into the management of NSCLC.

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024

NVL-655 has received FDA breakthrough therapy designation for patients with pretreated ALK-positive non-small cell lung cancer.

Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home

May 17th 2024

Jorge J. Nieva, MD, details the benefits of telemedicine and a first-of-its-kind clinical trial where patients with NSCLC will receive subcutaneous immunotherapy at home.

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024

The FDA has granted accelerated approval to tarlatamab for the treatment of patients with ES-SCLC with disease progression on or after platinum-based chemotherapy.

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16th 2024

Seeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15th 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15th 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Progress in SCLC: From Deadly to Cure?

May 15th 2024

Millie Das, MD, of Stanford Cancer Center, discusses the progress in small cell lung cancer treatment.

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024

Anne Chiang, MD, PhD, discusses understanding the heterogeneity of SCLC to determine which patients will respond to targeted therapy.

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in April 2024.

Repotrectinib Receives NMPA Approval in China for ROS1+ NSCLC

May 13th 2024

Repotrectinib has been approved by China’s National Medical Products Administration for the treatment of patients with ROS1-positive NSCLC.

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

May 10th 2024

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.